Journal of Biochemistry and Biotechnology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Mini Review - Journal of Biochemistry and Biotechnology (2023) Volume 6, Issue 3

Emerging immunotherapies for endocrine-related autoimmune diseases.

Michot Bigenwald*

Department of Medicine Oncology, Gustave Roussy Comprehensive Cancer Center, Villejuif, France

*Corresponding Author:
Michot Bigenwald
Department of Medicine Oncology
Gustave Roussy Comprehensive Cancer Center
Villejuif, France
E-mail:bi.michot@edu.org.fr

Received:25-May-2023,Manuscript No. AABB-23-104234; Editor assigned: 29-May-2023, PreQC No. AABB-23-104234(PQ); Reviewed:12-Jun-2023, QC No. AABB-23-104234; Revised:17-Jun-2023, Manuscript No. AABB-23-104234(R); Published:24-Jun-2023, DOI: 10.35841/aabb- 6.3.149

Citation: Ozalp G.A brief comment on immune escape pathways in cancer and overcoming resistance. J Cancer Immunol Ther. 2023;6(3):151

Visit for more related articles at Journal of Biochemistry and Biotechnology

Abstract

  

Introduction

Autoimmune diseases are a diverse group of disorders characterized by the immune system's abnormal response, leading to chronic inflammation and tissue damage. Endocrine-related autoimmune diseases specifically target the endocrine system, affecting hormone production and regulation. These disorders include type 1 diabetes mellitus, autoimmune thyroid diseases (e.g., Hashimoto's thyroiditis and Graves' disease), and Addison's disease. Although various treatment options exist, emerging immunotherapies are revolutionizing the management of endocrine-related autoimmune diseases. This article aims to explore the latest advancements in immunotherapies, highlighting their potential benefits and challenges[1].

Monoclonal antibodies

Monoclonal antibodies (mAbs) have emerged as powerful tools in treating endocrine-related autoimmune diseases. Specific mAbs, such as anti-CD3 and anti-CD20, have shown promising results in clinical trials. Anti-CD3 antibodies, such as teplizumab, target T cells and modulate their function, effectively slowing down the destruction of pancreatic beta cells in type 1 diabetes. Anti-CD20 antibodies, like rituximab, deplete B cells and have demonstrated efficacy in treating Graves' disease and other autoimmune thyroid disorders. Although mAbs hold great potential, their long-term safety and optimal dosing regimens require further investigation[2].

Immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by enhancing the immune system's ability to recognize and attack tumor cells. Recently, ICIs have shown promise in managing endocrine-related autoimmune diseases. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitors, such as ipilimumab, have exhibited efficacy in controlling type 1 diabetes progression by suppressing autoreactive T cells. Programmed cell death protein 1 (PD-1) inhibitors, such as pembrolizumab, have shown potential in managing autoimmune thyroid disorders. However, the use of ICIs in these contexts requires careful consideration due to the risk of inducing new autoimmune complications[3].

Regulatory t-cell therapy

Regulatory T cells (Tregs) play a crucial role in maintaining immune tolerance and preventing autoimmune diseases. Emerging immunotherapies aim to harness the power of Tregs to restore immune balance in endocrine-related autoimmune disorders. Adoptive transfer of ex vivo expanded Tregs, such as Treg infusion therapy, has shown promise in preclinical and early clinical trials for type 1 diabetes and autoimmune thyroid diseases. However, challenges related to Treg isolation, expansion, and long-term persistence limit their widespread application. Ongoing research focuses on optimizing Treg therapy protocols to achieve better outcomes[4].

Janus kinase inhibitors

Janus kinase (JAK) inhibitors have demonstrated significant efficacy in several autoimmune diseases, including rheumatoid arthritis and psoriasis. These drugs act by blocking intracellular signaling pathways involved in immune cell activation. In the context of endocrine-related autoimmune diseases, JAK inhibitors have shown promising results in managing both type 1 diabetes and autoimmune thyroid disorders. Baricitinib, an FDA-approved JAK inhibitor, has demonstrated the ability to preserve beta cell function and reduce insulin requirements in type 1 diabetes patients. Further clinical trials are underway to explore the potential of JAK inhibitors as a targeted therapy for endocrine-related autoimmune diseases.

Gene editing and cell-based therapies

Advancements in gene editing technologies, such as CRISPR-Cas9, have opened up new possibilities for precise and targeted interventions in autoimmune diseases. In the case of endocrine-related autoimmune disorders, gene editing can potentially correct genetic defects or modify immune cells to restore immune tolerance. Cell-based therapies, such as chimeric antigen receptor (CAR) T-cell therapy, hold promise in reprogramming the immune system to recognize and eliminate autoreactive cells. However, these approaches are still in the early stages of development and require further refinement and safety evaluation[5].

Conclusion

Emerging immunotherapies offer a new frontier in the treatment of endocrine-related autoimmune diseases. Monoclonal antibodies, immune checkpoint inhibitors, regulatory T cell therapy, Janus kinase inhibitors, and gene editing technologies are all promising approaches that hold potential for improving patient outcomes and quality of life. However, challenges related to long-term safety, optimal dosing, and patient selection need to be addressed. As research progresses and more clinical trials are conducted, we can expect these immunotherapies to play an increasingly vital role in managing endocrine-related autoimmune diseases, offering hope to patients worldwide.

References

  1. Chen TW, Razak AR, Bedard PL, et al.A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.Ann Oncol. 2015;26(9):1824-9.

    2. Indexed at, Google Scholar, Cross Ref

  2. Barjaktarevic IZ, Qadir N, Suri A, et al.Organizing pneumonia as a side effect of ipilimumab treatment of melanoma.Chest. 2013;143(3):858-61.

    3. Indexed at, Google Scholar,Cross Ref

  3. Song GG, Kim JH, Kim YH, et al.Association between CTLA-4 polymorphisms and susceptibility to Celiac disease: A meta-analysis.Human Immunol. 2013;74(9):1214-8.

    4. Indexed at, Google Scholar, Cross Ref

  4. Hodi FS, O'day SJ, McDermott DF, et al.Improved survival with ipilimumab in patients with metastatic melanoma.New England J Med. 2010;363(8):711-23.

    5. Indexed at, Google Scholar, Cross Ref

  5. Gajewski TF, Louahed J, Brichard VG.Gene signature in melanoma associated with clinical activity: A potential clue to unlock cancer immunotherapy.Cancer J. 2010;16(4):399-403.

    6. Indexed at, Google Scholar, Cross Ref

Get the App